Cancer Immunology research within MCBI


The overall goal of our translational research in the field of Cancer Immunology is to investigate new immunotherapy's  by vaccination and antibody therapy. We focus on both the tumor specific innate and the adaptive immunity overcoming the tumor suppressive tumor micromilieu. We develop new multiparameter immune monitoring panels and analyse novel immune suppressive molecular players within the tumor microenvironment to interfere with to further improve immune diagnostics and  the design of novel immunotherapy's. Our focus is on melanoma, colonrectal and pancreatic cancer and glioblastoma.


We use in vitro and in vivo models for melanoma, colon, pancreatic cancer and glioblastoma. We design and synthesize DC targeting nanovaccines  modified peptidenetworks, and have multiparameter  parameter  CYTOF analysis and microscopy analysis  and firefly imaging systems to analyse immunological responses. We use antibody treatments in the metastatic formation of tumors. Moreover using CRISPR-Cas we modify regulatory glycosylation mechanisms in tumor to study their effects on tumorimmunity.  One of our major strengths is that we have access to well-characterized patients samples that allowing us to translate our fundmental  findings to clinical applications.

1. DC cancer vaccines and biology  -  group Van Kooyk
2. Antibody treatment - group Van Egmond
3. Tumor microenvironment - group Van Vliet
4. Immunomonitoring - group Garcia Vallejo
5. Myeloid cells in adaptive immunity -  group Den Haan
6. Translational Macrophage Immunometabolism - group Van den Bossche